RenaissanceRe (RNR) Q3 2025 earnings summary

Executive summary

• Net income available to common shareholders was $907.7M and operating income was $733.7M for Q3 2025, with EPS of $19.40 and $15.62, respectively; annualized ROE was 34.9% and operating ROE was 28.2%.

• Book value per common share increased 9.0% in the quarter to $231.23, and tangible book value per share plus accumulated dividends rose 10.3% in the quarter and 21.8% year-to-date.

• Underwriting income rose to $770.2M, driven by lower catastrophe losses and favorable prior year development in the Property segment.

• Strategic focus on underwriting margin, capital partner fees, and investment income growth, with fee income up 24.1% to $101.8M.

• Share repurchases totaled $205.2M in Q3, with an additional $100M repurchased in October; over $1B returned to shareholders YTD.

Financial highlights

• Gross premiums written were $2.32B, down 3.2% year-over-year; net premiums written were $2.06B, down 4.8%; net premiums earned were $2.43B, down 5.8%.

• Combined ratio improved to 68.4% from 84.8% last year; adjusted combined ratio was 66.6%.

• Net investment income was $438.4M, up $14.5M year-over-year; total investment result was $750.2M, including $311.9M net realized/unrealized gains.

• Underwriting income: $770M; fee income: $101.8M.

• Book value per common share increased to $231.23 at September 30, 2025.

Outlook and guidance

• Management expects continued strong capital position and flexibility to deploy capital into business or repurchase shares, with confidence in sustaining strong earnings and generating long-term value.

• Attractive underwriting opportunities anticipated at January 1 renewals, focusing on disciplined portfolio construction and margin over growth.

• Property catastrophe rates expected to decline ~10% at January 1 renewal, but returns remain well above cost of capital.

• Management fees expected at ~$50M and performance fees at ~$30M in Q4, barring large losses.

• Other property net premiums earned expected at ~$360M in Q4; casualty and specialty at ~$1.5B, with high 90s combined ratio.